Showing 861-870 of 1564 results for "".
- Regenerative Dermatology Company Forms Strategic Manufacturing Partnership with Innovigenhttps://reachmd.com/news/regenerative-dermatology-company-forms-strategic-manufacturing-partnership-with-innovigen/2476008/Robles BioCeutics, a regenerative dermatology company focused on senolytic and stem cell-powered skincare, has entered a strategic manufacturing partnership with Innovigen, a California-based formulation and production company specializing in cosmetic GMP manufacturing. The agreement represents a
- The Role of TMEM219 Inhibition in Restoring Mucosal Integrity in Inflammatory Bowel Diseaseshttps://reachmd.com/news/the-role-of-tmem219-inhibition-in-restoring-mucosal-integrity-in-inflammatory-bowel-diseases/2474699/Innovative international research led by Paolo Fiorina confirms that inhibiting TMEM219 can restore mucosal healing in patients with inflammatory bowel diseases by preventing the death of intestinal epithelial stem cells and enhancing repair. This brea
- Therapeutic Advances in IgA Nephropathy: Atacicept and B-Cell Modulationhttps://reachmd.com/news/iga-nephropathy-atacicept-b-cell-modulation/2484843/Atacicept for the treatment of IgAN has entered the FDA accelerated Biologics License Application pathw
- CAR T Cell Therapy: A Novel Approach to Combating Atherosclerosishttps://reachmd.com/news/car-t-cell-therapy-a-novel-approach-to-combating-atherosclerosis/2484572/Engineered anti‑OxLDL CAR Tregs cut aortic plaque by ~70% in high‑cholesterol mice, suggesting a potential inflammation‑targeted strategy for residual atherosclerotic risk. In
- Breakthrough Dual-action mRNA Vaccine Targets Merkel Cell Carcinomahttps://reachmd.com/news/breakthrough-dual-action-mrna-vaccine-targets-merkel-cell-carcinoma/2484321/Yale researchers have developed a dual-action mRNA vaccine that tar
- Breakthroughs in Cancer Immunotherapy: Enhancing Immune Cells and Targeting Genetic Drivershttps://reachmd.com/news/breakthroughs-in-cancer-immunotherapy-enhancing-immune-cells-and-targeting-genetic-drivers/2476026/Cancer immunotherapy has revolutionized treatment strategies, yet challenges persist in optimizing immune response and directly targeting genetic drivers like KRAS and MYC. Recent advances in technology offer promising solutions. As oncologists confront tumors that evade current moda
- Innovative Approaches in Sickle Cell Management: Combating Acute Chest Syndromehttps://reachmd.com/news/innovative-approaches-in-sickle-cell-management-combating-acute-chest-syndrome/2475725/Recent clinical data underscore that acute chest syndrome continues to drive significant morbidity, mortality,
- Assessment of DLL3/CD3 T-cell Engager Obrixtamig for Neuroendocrine Carcinomashttps://reachmd.com/news/assessment-of-dll3cd3-t-cell-engager-obrixtamig-for-neuroendocrine-carcinomas/2475628/
- C5aR1: A Critical Biomarker for Metastasis in Cutaneous Squamous Cell Carcinomahttps://reachmd.com/news/c5ar1-a-critical-biomarker-for-metastasis-in-cutaneous-squamous-cell-carcinoma/2474919/Recent identification of complement component 5a receptor 1 (C5aR1) as a critical metastasis biomarker may improve risk stratification and patient management i
- First Patient Dosed with GPX4 Modulator Targeting Pathologic Senescent Cellshttps://reachmd.com/news/first-patient-dosed-with-gpx4-modulator-targeting-pathologic-senescent-cells/2475369/The first patient has been dosed with the lead drug candidate RLS-1496 in a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial, Rubedo Life Sciences, Inc., announced in a press release. The study marks the first time a glutathio